{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:26:11Z","timestamp":1781184371210,"version":"3.54.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00210-024-02994-z","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:01:55Z","timestamp":1707811315000},"page":"4643-4656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists"],"prefix":"10.1007","volume":"397","author":[{"given":"Simran","family":"Soni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir S.","family":"Lukhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baban S.","family":"Thawkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Chintamaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Ramniwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep Singh","family":"Tuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"issue":"2","key":"2994_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11302-021-09774-x","volume":"17","author":"X Ai","year":"2021","unstructured":"Ai X et al (2021) Targeting P2 receptors in purinergic signaling: a new strategy of active ingredients in traditional Chinese herbals for diseases treatment. Purinergic Signal 17(2):229\u2013240. https:\/\/doi.org\/10.1007\/s11302-021-09774-x","journal-title":"Purinergic Signal"},{"issue":"S1","key":"2994_CR2","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1111\/bph.14749","volume":"176","author":"SPH Alexander","year":"2019","unstructured":"Alexander SPH et al (2019) The concise guide to pharmacology 2019\/20: ion channels. Br J Pharmacol 176(S1):S142\u2013S228. https:\/\/doi.org\/10.1111\/bph.14749","journal-title":"Br J Pharmacol"},{"key":"2994_CR3","unstructured":"Ando K et al (2020) Tetrahydroquinoline derivatives as P2x7 receptor antagonists. AU-2018235561-B2 18th June 2020. https:\/\/patents.google.com\/patent\/AU2018235561B2\/en"},{"issue":"July","key":"2994_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2020.00124","volume":"13","author":"R Andrejew","year":"2020","unstructured":"Andrejew R et al (2020) The P2X7 receptor: central hub of brain diseases. Front Mol Neurosci 13(July):1\u201327. https:\/\/doi.org\/10.3389\/fnmol.2020.00124","journal-title":"Front Mol Neurosci"},{"issue":"9","key":"2994_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1242\/dmm.017038","volume":"7","author":"S Apolloni","year":"2014","unstructured":"Apolloni S et al (2014) Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. DMM Disease Models and Mechanisms 7(9):1101\u20131109. https:\/\/doi.org\/10.1242\/dmm.017038","journal-title":"DMM Disease Models and Mechanisms"},{"key":"2994_CR6","doi-asserted-by":"publisher","unstructured":"Apolloni S et al (2021) Novel P2X7 antagonist ameliorates the early phase of ALS disease and decreases inflammation and autophagy in SOD1-G93A mouse model. Int J Mol Sci 22(19):10649.\u00a0https:\/\/doi.org\/10.3390\/ijms221910649","DOI":"10.3390\/ijms221910649"},{"key":"2994_CR7","unstructured":"Artyomov M, Lampropoulou V (2017) Immunomoudulatory agents and methods of use thereof. WO2017142855A1 24th Aug 2017. https:\/\/patents.google.com\/patent\/WO2017142855A1\/en"},{"key":"2994_CR8","unstructured":"Artyomov M et al (2020) Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response US-20200375929-A1 3rd Dec 2020. https:\/\/patents.google.com\/patent\/US20200375929A1\/en"},{"key":"2994_CR9","unstructured":"Barden JA (2016) Pain treatment. WO-2016154683-A1 6th Oct 2016. https:\/\/patents.google.com\/patent\/WO2016154683A1\/en"},{"issue":"47","key":"2994_CR10","doi-asserted-by":"publisher","first-page":"33206","DOI":"10.1074\/jbc.274.47.33206","volume":"274","author":"OR Baricordi","year":"1999","unstructured":"Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, Di Virgilio F (1999) Increased proliferation rate of lymphoid cells transfected with the P2X 7 ATP receptor. J Biol Chem 274(47):33206\u201333208. https:\/\/doi.org\/10.1074\/jbc.274.47.33206","journal-title":"J Biol Chem"},{"key":"2994_CR11","doi-asserted-by":"publisher","unstructured":"Bartlett R, Sluyter V, Watson D, Sluyter R, Yerbury JJ (2017) P2X7 antagonism using brilliant blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice. PeerJ. 5:e3064.\u00a0https:\/\/doi.org\/10.7717\/peerj.3064","DOI":"10.7717\/peerj.3064"},{"key":"2994_CR12","doi-asserted-by":"publisher","unstructured":"Bengtsson T, Scott K (2010) The ageing population. Demographic research monographs, pp. 7\u201322. https:\/\/doi.org\/10.1007\/978-3-642-12612-3_2","DOI":"10.1007\/978-3-642-12612-3_2"},{"key":"2994_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fphar.2018.00030","volume":"9","author":"A Bhattacharya","year":"2018","unstructured":"Bhattacharya A (2018) Recent advances in CNS P2X7 physiology and pharmacology: focus on neuropsychiatric disorders. Front Pharmacol 9:30. https:\/\/doi.org\/10.3389\/fphar.2018.00030","journal-title":"Front Pharmacol"},{"key":"2994_CR14","doi-asserted-by":"publisher","unstructured":"Bibi\u010d L, Stokes L (2020) Revisiting the idea that amyloid-\u03b2 peptide acts as an agonist for P2X7. Front Mol Neurosci 13:166.\u00a0https:\/\/doi.org\/10.3389\/fnmol.2020.00166","DOI":"10.3389\/fnmol.2020.00166"},{"issue":"3","key":"2994_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1124\/mol.119.116715","volume":"96","author":"A Bin Dayel","year":"2019","unstructured":"Bin Dayel A, Evans RJ, Schmid R (2019) Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, calmidazolium, and zinc 58368839 to the intersubunit allosteric pocket. Mol Pharmacol 96(3):355\u2013363. https:\/\/doi.org\/10.1124\/mol.119.116715","journal-title":"Mol Pharmacol"},{"issue":"3","key":"2994_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1124\/mol.119.116715","volume":"96","author":"A Bin Dayel","year":"2019","unstructured":"Bin Dayel A, Evans RJ, Schmid R (2019) Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, calmidazolium, and Zinc58368839 to the intersubunit allosteric pocket. Mol Pharmacol 96(3):355\u2013363. https:\/\/doi.org\/10.1124\/mol.119.116715","journal-title":"Mol Pharmacol"},{"key":"2994_CR17","unstructured":"Boughton-Smith N, Cruwys S (2005) A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug. WO2005025571A1 24th March 2005. https:\/\/patents.google.com\/patent\/WO2005025571A1\/en"},{"key":"2994_CR18","unstructured":"Brotherton-Pleiss CE, Keith A, Walker M (2012) Amido compounds. no. US 2012\/0149718 A1 14th June 2012. https:\/\/patents.google.com\/patent\/US20120149718A1\/en"},{"key":"2994_CR19","unstructured":"Bryson N (2021) Activation of P2x7 receptors with non-benzazepine adenosine triphosphate derivatives. US-20210100826-A1 8th April 2021. https:\/\/patents.google.com\/patent\/US20210100826A1\/en?oq=US-20210100826-A1"},{"issue":"1","key":"2994_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-017-9593-0","volume":"14","author":"G Burnstock","year":"2018","unstructured":"Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14(1):1\u201318. https:\/\/doi.org\/10.1007\/s11302-017-9593-0","journal-title":"Purinergic Signal"},{"key":"2994_CR21","unstructured":"Buyse MA, Stortelers C (2020) P2x7 receptor binders and polypeptides comprising the same. US10875918B2 29th Dec 2020. https:\/\/patents.google.com\/patent\/US10875918B2\/en?oq=US10875918B2"},{"key":"2994_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuropharm.2014.01.045","volume":"81","author":"MRS Carmo","year":"2014","unstructured":"Carmo MRS et al (2014) The P2X7 receptor antagonist brilliant blue G attenuates contralateral rotations in a rat model of parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis. Neuropharmacology 81:142\u2013152. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.01.045","journal-title":"Neuropharmacology"},{"key":"2994_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fncel.2013.00273","volume":"7","author":"T Chataigneau","year":"2013","unstructured":"Chataigneau T, Lemoine D, Grutter T (2013) Exploring the ATP-binding site of P2X receptors. Front Cell Neurosci 7:273. https:\/\/doi.org\/10.3389\/fncel.2013.00273","journal-title":"Front Cell Neurosci"},{"issue":"9967","key":"2994_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(14)61462-8","volume":"385","author":"S Chatterji","year":"2015","unstructured":"Chatterji S, Byles J, Cutler D, Seeman T, Verdes E (2015) Health, functioning, and disability in older adults - present status and future implications. The Lancet 385(9967):563\u2013575. https:\/\/doi.org\/10.1016\/S0140-6736(14)61462-8","journal-title":"The Lancet"},{"key":"2994_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroscience.2014.08.036","volume":"279","author":"X Chen","year":"2014","unstructured":"Chen X et al (2014) Brilliant blue G improves cognition in an animal model of Alzheimer\u2019s disease and inhibits amyloid-\u03b2-induced loss of filopodia and dendrite spines in hippocampal neurons. Neuroscience 279:94\u2013101. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.08.036","journal-title":"Neuroscience"},{"issue":"4","key":"2994_CR26","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","volume":"13","author":"WW Chen","year":"2016","unstructured":"Chen WW, Zhang X, Huang WJ (2016) Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 13(4):3391\u20133396. https:\/\/doi.org\/10.3892\/mmr.2016.4948","journal-title":"Mol Med Rep"},{"issue":"3","key":"2994_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1124\/pr.110.003129","volume":"63","author":"C Coddou","year":"2011","unstructured":"Coddou C, Yan Z, Obsil T, Pablo Huidobro-Toro J, Stojilkovic SS (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63(3):641\u2013683. https:\/\/doi.org\/10.1124\/pr.110.003129","journal-title":"Pharmacol Rev"},{"issue":"7","key":"2994_CR28","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.4049\/jimmunol.0901212","volume":"183","author":"N D\u2019Ambrosi","year":"2009","unstructured":"D\u2019Ambrosi N et al (2009) The pro-inflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J Immunol 183(7):4648\u20134656. https:\/\/doi.org\/10.4049\/jimmunol.0901212","journal-title":"J Immunol"},{"issue":"November","key":"2994_CR29","doi-asserted-by":"publisher","first-page":"104714","DOI":"10.1016\/j.neuint.2020.104714","volume":"136","author":"AP de Ara\u00fajoBoleti","year":"2020","unstructured":"de Ara\u00fajoBoleti AP, de Oliveira Flores TM, Moreno SE, dos Anjos L, Mortari MR, Migliolo L (2020) Neuroinflammation: an overview of neurodegenerative and metabolic diseases and of biotechnological studies. Neurochem Int 136(November):104714. https:\/\/doi.org\/10.1016\/j.neuint.2020.104714","journal-title":"Neurochem Int"},{"key":"2994_CR30","unstructured":"Dean DK et al (2013) 5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [4, 3-a] pyrazine derivatives as P2X7 modulators. US8501946B, 6 Aug. 2013. https:\/\/patents.google.com\/patent\/US8501946B2\/en"},{"key":"2994_CR31","unstructured":"Dean DK et al (2016) 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2x7 modulators. EP2424869B1, 22nd June 2016. https:\/\/patents.google.com\/patent\/EP2424869B1\/en?oq=EP2424869B1"},{"issue":"8","key":"2994_CR32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.neurobiolaging.2011.09.040","volume":"33","author":"JI Diaz-Hernandez","year":"2012","unstructured":"Diaz-Hernandez JI et al (2012) In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer\u2019s disease through GSK3\u03b2 and secretases. Neurobiol Aging 33(8):1816\u20131828. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.09.040","journal-title":"Neurobiol Aging"},{"key":"2994_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jnc.13607","volume":"139","author":"DJ DiSabato","year":"2016","unstructured":"DiSabato DJ, Quan N, Godbout JP (2016) Neuroinflammation: the devil is in the details. J Neurochem 139:136\u2013153. https:\/\/doi.org\/10.1111\/jnc.13607","journal-title":"J Neurochem"},{"key":"2994_CR34","unstructured":"Dombroski MA, Duplantier AJ (2007) Benzamide inhibitors of the P2x7 receptor. US7176202B2 13th Feb 2007. https:\/\/patents.google.com\/patent\/US7176202B2\/en"},{"key":"2994_CR35","unstructured":"Dombroski MA, Duplantier AJ, Subramanyam C (2012) Benzamide inhibitors of the P2x7 receptor. EP1837330A1 24th Oct 2012. https:\/\/patents.google.com\/patent\/EP1837330A1\/en"},{"issue":"2","key":"2994_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vision1020014","volume":"1","author":"M Dutot","year":"2017","unstructured":"Dutot M, Olivier E, Wakx A, Rat P (2017) The role of the p2x7 receptor in ocular stresses: a potential therapeutic target. Vision (switzerland) 1(2):1\u201311. https:\/\/doi.org\/10.3390\/vision1020014","journal-title":"Vision (switzerland)"},{"key":"2994_CR37","unstructured":"Fava E et al (2021) Methods for assigning a phenotypic signature for diagnostic and therapeutic applications. WO2021152173 5th August 2021. https:\/\/patents.google.com\/patent\/WO2021152173A1\/en"},{"key":"2994_CR38","doi-asserted-by":"publisher","unstructured":"Fonteles AA et al (2020) ATP signaling controlling dyskinesia through P2X7 receptors. Front Mol Neurosci 13:111. https:\/\/doi.org\/10.3389\/fnmol.2020.00111","DOI":"10.3389\/fnmol.2020.00111"},{"key":"2994_CR39","unstructured":"Fowler DH (2021) ALS treatment using induced regulatory T (ITREG) cells. US20210275591 9th Sep 2021. https:\/\/patents.google.com\/patent\/US20210275591\/en"},{"key":"2994_CR40","doi-asserted-by":"publisher","unstructured":"Francistiov\u00e1 L et al (2020) The role of P2X7 receptor in Alzheimer\u2019s disease.\u00a0Front Mol Neurosci 13:94. https:\/\/doi.org\/10.3389\/fnmol.2020.00094","DOI":"10.3389\/fnmol.2020.00094"},{"issue":"1","key":"2994_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/157488910789753530","volume":"5","author":"SA Friedle","year":"2010","unstructured":"Friedle SA, Curet MA, Watters JJ (2010) Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov 5(1):35\u201345. https:\/\/doi.org\/10.2174\/157488910789753530","journal-title":"Recent Pat CNS Drug Discov"},{"issue":"April","key":"2994_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00793","volume":"10","author":"AL Giuliani","year":"2019","unstructured":"Giuliani AL et al (2019) The P2X7 receptor is shed into circulation: correlation with C-reactive protein levels. Front Immunol 10(April):1\u20137. https:\/\/doi.org\/10.3389\/fimmu.2019.00793","journal-title":"Front Immunol"},{"key":"2994_CR43","unstructured":"Guile SD, Thompson T (2012a) Quinoline derivatives 057.no. US 8106073 B2 31st Jan 2012. https:\/\/patents.google.com\/patent\/US8106073B2\/en"},{"key":"2994_CR44","unstructured":"Guile SD, Thompson T (2012b) Quinoline derivatives 057. U.S. Patent No. 8 106 073 31 Jan. 2012. https:\/\/patents.google.com\/patent\/US8106073B2\/en"},{"issue":"1","key":"2994_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1146\/annurev-cellbio-100616-060509","volume":"34","author":"TR Hammond","year":"2018","unstructured":"Hammond TR, Robinton D, Stevens B (2018) Microglia and the brain: complementary partners in development and disease. Annu Rev Cell Dev Biol 34(1):523\u2013544. https:\/\/doi.org\/10.1146\/annurev-cellbio-100616-060509","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"5","key":"2994_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MNM.0000000000000660","volume":"38","author":"J Han","year":"2017","unstructured":"Han J et al (2017) Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11 C]GSK1482160 for neuroinflammatory response. Nucl Med Commun 38(5):372\u2013382. https:\/\/doi.org\/10.1097\/MNM.0000000000000660","journal-title":"Nucl Med Commun"},{"issue":"Suppl 1","key":"2994_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-018-0721-7","volume":"19","author":"Z Han","year":"2018","unstructured":"Han Z et al (2018) Parkinson\u2019s disease and Alzheimer\u2019s disease: a Mendelian randomization study. BMC Med Genet 19(Suppl 1):1\u20139. https:\/\/doi.org\/10.1186\/s12881-018-0721-7","journal-title":"BMC Med Genet"},{"key":"2994_CR48","doi-asserted-by":"publisher","unstructured":"Hemonnot AL, Hua J, Ulmann L, Hirbec H (2019) Microglia in Alzheimer disease: well-known targets and new opportunities. Front Cell Infect Microbiol 11:233. https:\/\/doi.org\/10.3389\/fnagi.2019.00233","DOI":"10.3389\/fnagi.2019.00233"},{"issue":"17","key":"2994_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21175996","volume":"21","author":"P Illes","year":"2020","unstructured":"Illes P (2020) P2x7 receptors amplify cns damage in neurodegenerative diseases. International Journal of Molecular Sciences 21(17):1\u201331. https:\/\/doi.org\/10.3390\/ijms21175996","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"2994_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrd4334","volume":"13","author":"RR Ji","year":"2014","unstructured":"Ji RR, Xu ZZ, Gao YJ (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13(7):533\u2013548. https:\/\/doi.org\/10.1038\/nrd4334","journal-title":"Nat Rev Drug Discov"},{"key":"2994_CR51","unstructured":"Jinwal UK, Sutariya VB (2020) Preparation and characterization of methylene blue nanoparticles for Alzheimer\u2019s disease and other tauopathies. US10765755 8th Sep 2020. https:\/\/patents.google.com\/patent\/US10765755B1\/en"},{"issue":"September","key":"2994_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2019.00401","volume":"13","author":"JM Kanellopoulos","year":"2019","unstructured":"Kanellopoulos JM, Delarasse C (2019) Pleiotropic roles of P2X7 in the central nervous system. Front Cell Neurosci 13(September):1\u201318. https:\/\/doi.org\/10.3389\/fncel.2019.00401","journal-title":"Front Cell Neurosci"},{"key":"2994_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2017.00216","volume":"11","author":"D Kempuraj","year":"2017","unstructured":"Kempuraj D et al (2017) Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration. Front Cell Neurosci 11:1\u201316. https:\/\/doi.org\/10.3389\/fncel.2017.00216","journal-title":"Front Cell Neurosci"},{"key":"2994_CR54","unstructured":"Laeremans T et al (2018) Method for generation of immunoglobulin sequences. US-10023633-B2 17th July 2018. https:\/\/patents.google.com\/patent\/US10023633B2\/en"},{"key":"2994_CR55","unstructured":"Lee PP, Draganov D (2017) Macrocyclic lactones and uses thereof as modulators of purinergic receptors. US-20170119807-A1, 13th July 2017. https:\/\/patents.google.com\/patent\/US20170119807A1\/en"},{"issue":"11","key":"2994_CR56","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1021\/acs.jmedchem.7b00408","volume":"60","author":"MA Letavic","year":"2017","unstructured":"Letavic MA et al (2017) 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate. J Med Chem 60(11):4559\u20134572. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00408","journal-title":"J Med Chem"},{"key":"2994_CR57","unstructured":"Levy Y, Lelievre JD, Menkova-Garnier I (2020) P2x7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (hiv). no. US 10548980 B2, 4th Feb 2020. https:\/\/patents.google.com\/patent\/US10548980B2\/en"},{"key":"2994_CR58","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bbi.2020.10.007","volume":"91","author":"L Li","year":"2021","unstructured":"Li L, Acioglu C, Heary RF, Elkabes S (2021) Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases. Brain Behav Immun 91:740\u2013755. https:\/\/doi.org\/10.1016\/j.bbi.2020.10.007","journal-title":"Brain Behav Immun"},{"issue":"2","key":"2994_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/svn-2016-000012","volume":"1","author":"H Liu","year":"2016","unstructured":"Liu H, Leak RK, Hu X (2016) Neurotransmitter receptors on microglia. Stroke Vasc Neurol 1(2):52\u201358. https:\/\/doi.org\/10.1136\/svn-2016-000012","journal-title":"Stroke Vasc Neurol"},{"key":"2994_CR60","unstructured":"Liu PS et al (2020) Heripenes with pain-relieving effect, active substances of Hericium erinaceus mycelium and the preparation method thereof, and pharmaceutical composition containing the heripenes or active substances. US20200068815 5th Mar 2020. https:\/\/patents.google.com\/patent\/US20200068815A1\/en"},{"issue":"FEB","key":"2994_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2015.00054","volume":"9","author":"A Lourbopoulos","year":"2015","unstructured":"Lourbopoulos A, Ert\u00fcrk A, Hellal F (2015) Microglia in action: how aging and injury can change the brain\u2019s guardians. Front Cell Neurosci 9(FEB):1\u20138. https:\/\/doi.org\/10.3389\/fncel.2015.00054","journal-title":"Front Cell Neurosci"},{"key":"2994_CR62","doi-asserted-by":"publisher","unstructured":"Lukens JR, Eyo UB (2022)\u00a0Microglia and neurodevelopmental disorders.\u00a0Annu Rev Neurosci 45:425\u2013445. https:\/\/doi.org\/10.1146\/annurev-neuro-110920","DOI":"10.1146\/annurev-neuro-110920"},{"issue":"1","key":"2994_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11302-020-09692-4","volume":"16","author":"D Ly","year":"2020","unstructured":"Ly D et al (2020) The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice. Purinergic Signal 16(1):109\u2013122. https:\/\/doi.org\/10.1007\/s11302-020-09692-4","journal-title":"Purinergic Signal"},{"issue":"23","key":"2994_CR64","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1242\/jcs.207365","volume":"130","author":"A Malik","year":"2017","unstructured":"Malik A, Kanneganti TD (2017) Inflammasome activation and assembly at a glance. J Cell Sci 130(23):3955\u20133963. https:\/\/doi.org\/10.1242\/jcs.207365","journal-title":"J Cell Sci"},{"issue":"6","key":"2994_CR65","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00702-010-0400-0","volume":"117","author":"D Marcellino","year":"2010","unstructured":"Marcellino D et al (2010) On the role of P2X7 receptors in dopamine nerve cell degeneration in a rat model of Parkinson\u2019s disease: studies with the P2X 7 receptor antagonist A-438079. J Neural Transm 117(6):681\u2013687. https:\/\/doi.org\/10.1007\/s00702-010-0400-0","journal-title":"J Neural Transm"},{"issue":"1","key":"2994_CR66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41380-018-0108-3","volume":"24","author":"E Martin","year":"2019","unstructured":"Martin E et al (2019) New role of P2X7 receptor in an Alzheimer\u2019s disease mouse model. Mol Psychiatry 24(1):108\u2013125. https:\/\/doi.org\/10.1038\/s41380-018-0108-3","journal-title":"Mol Psychiatry"},{"issue":"22","key":"2994_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21228454","volume":"21","author":"M\u00c1 Mart\u00ednez-cuesta","year":"2020","unstructured":"Mart\u00ednez-cuesta M\u00c1, Blanch-ruiz MA, Ortega-luna R, S\u00e1nchez-l\u00f3pez A, \u00c1lvarez \u00c1 (2020) Structural and functional basis for understanding the biological significance of p2x7 receptor. Int J Mol Sci 21(22):1\u201323. https:\/\/doi.org\/10.3390\/ijms21228454","journal-title":"Int J Mol Sci"},{"key":"2994_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.neuro.26.043002.094919","volume":"26","author":"R Mayeux","year":"2003","unstructured":"Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81\u2013104. https:\/\/doi.org\/10.1146\/annurev.neuro.26.043002.094919","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"2994_CR69","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cell.2019.09.017","volume":"179","author":"AE McCarthy","year":"2019","unstructured":"McCarthy AE, Yoshioka C, Mansoor SE (2019) Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization. Cell 179(3):659-670.e13. https:\/\/doi.org\/10.1016\/j.cell.2019.09.017","journal-title":"Cell"},{"key":"2994_CR70","unstructured":"Meyer J et al (2020) Predictive markers of brain inflammation. WO2020237379. 3 Dec 2020. https:\/\/patents.google.com\/patent\/WO2020237379A1\/en"},{"key":"2994_CR71","doi-asserted-by":"publisher","first-page":"114472","DOI":"10.1016\/j.bcp.2021.114472","volume":"187","author":"MT Miras-Portugal","year":"2021","unstructured":"Miras-Portugal MT, Ortega F, G\u00f3mez-Villafuertes R, Gualix J, P\u00e9rez-Sen R, Delicado EG (2021) P2X7 receptors in the central nervous system. Biochem Pharmacol 187:114472. https:\/\/doi.org\/10.1016\/j.bcp.2021.114472","journal-title":"Biochem Pharmacol"},{"key":"2994_CR72","doi-asserted-by":"publisher","first-page":"654739","DOI":"10.3389\/fneur.2021.654739","volume":"12","author":"I Mortada","year":"2021","unstructured":"Mortada I et al (2021) Immunotherapies for neurodegenerative diseases. Front Neurol 12:654739. https:\/\/doi.org\/10.3389\/fneur.2021.654739","journal-title":"Front Neurol"},{"issue":"2","key":"2994_CR73","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bbrc.2013.03.079","volume":"434","author":"J Ni","year":"2013","unstructured":"Ni J, Wang P, Zhang J, Chen W, Gu L (2013) Silencing of the P2X7 receptor enhances amyloid-\u03b2 phagocytosis by microglia. Biochem Biophys Res Commun 434(2):363\u2013369. https:\/\/doi.org\/10.1016\/j.bbrc.2013.03.079","journal-title":"Biochem Biophys Res Commun"},{"issue":"March","key":"2994_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuint.2018.07.003","volume":"120","author":"R Niranjan","year":"2018","unstructured":"Niranjan R (2018) Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration. Neurochem Int 120(March):13\u201320. https:\/\/doi.org\/10.1016\/j.neuint.2018.07.003","journal-title":"Neurochem Int"},{"key":"2994_CR75","unstructured":"Ogawa T, Kai H, Hirai K (2020) 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same. US10774051B2 15th Sep 2020. https:\/\/patents.google.com\/patent\/US10774051B2\/en"},{"key":"2994_CR76","unstructured":"Ogino M et al (2020) Aromatic ring compound. US10548877B2 4th Feb 2020. https:\/\/patents.google.com\/patent\/US10548877B2\/en"},{"key":"2994_CR77","doi-asserted-by":"publisher","unstructured":"Oliveira-Giacomelli \u00c1 et al (2019) P2Y6 and P2X7 receptor antagonism exerts neuroprotective and neuroregenerative effects in an animal model of Parkinson\u2019s disease. Front Cell Neurosci 13:476. https:\/\/doi.org\/10.3389\/fncel.2019.00476","DOI":"10.3389\/fncel.2019.00476"},{"key":"2994_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.00058","volume":"9","author":"G Pasqualetto","year":"2018","unstructured":"Pasqualetto G, Brancale A, Young MT (2018) The molecular determinants of small-molecule ligand binding at P2X receptors. Front Pharmacol 9:1\u201313. https:\/\/doi.org\/10.3389\/fphar.2018.00058","journal-title":"Front Pharmacol"},{"key":"2994_CR79","unstructured":"Pevarello P, Prandi A (2020) Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide And N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2x7 receptor antagonists. US10669267B2 6th Feb 2020. https:\/\/patents.google.com\/patent\/US10669267B2\/en"},{"key":"2994_CR80","unstructured":"Pevarello P et al (2018) 2-chloro-n-[2-(1,3-thiazol-5-yl)ethyl]-5-(5-fluoropyrimidin-2-yl)-benzamides and their use as P2x7 receptor antagonists. EP-3290417-A1, 7th March 2018. https:\/\/patents.google.com\/patent\/EP3290417A1\/en"},{"key":"2994_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115975","volume":"31","author":"E Pislyagin","year":"2021","unstructured":"Pislyagin E et al (2021) Synthetic 1,4-Naphthoquinones inhibit P2X7 receptors in murine neuroblastoma cells. Bioorg Med Chem 31:115975. https:\/\/doi.org\/10.1016\/j.bmc.2020.115975","journal-title":"Bioorg Med Chem"},{"key":"2994_CR82","unstructured":"Prince M, Albanese E, Guerchet M, Prina M (2014) World Alzheimer report 2014 dementia and risk reduction an analysis of protective and modifiable factors. In: ResearchGate. https:\/\/www.researchgate.net\/publication\/266088301_World_Alzheimer_Report_2014_Dementia_and_Risk_Reduction_An_Analysis_of_Protective_and_Modifiable_Factors. Accessed 8 Feb 2024"},{"key":"2994_CR83","unstructured":"Radetich B, Yu B, Zhu Y (2016) Heterocyclic derivatives. US-9458163-B2 4th Oct 2016. https:\/\/patents.google.com\/patent\/US9458163B2\/en"},{"issue":"16","key":"2994_CR84","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1016\/j.bmcl.2016.06.048","volume":"26","author":"JC Rech","year":"2016","unstructured":"Rech JC, Bhattacharya A, Letavic MA, Savall BM (2016) The evolution of P2X7 antagonists with a focus on CNS indications\u201d. Bioorganic and Medicinal Chemistry Letters 26(16):3838\u20133845. https:\/\/doi.org\/10.1016\/j.bmcl.2016.06.048","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"issue":"June","key":"2994_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2020.00093","volume":"13","author":"C Ruiz-Ruiz","year":"2020","unstructured":"Ruiz-Ruiz C, Calzaferri F, Garc\u00eda AG (2020) P2x7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis. Front Mol Neurosci 13(June):1\u201313. https:\/\/doi.org\/10.3389\/fnmol.2020.00093","journal-title":"Front Mol Neurosci"},{"key":"2994_CR86","doi-asserted-by":"publisher","unstructured":"Ruiz-Ruiz C et al (2020) Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice.\u00a0Dis Model Mech\u00a013(10):dmm045732. https:\/\/doi.org\/10.1242\/dmm.045732","DOI":"10.1242\/dmm.045732"},{"key":"2994_CR87","doi-asserted-by":"publisher","unstructured":"Sita G, Graziosi A, Hrelia P, Morroni F (2021) Nlrp3 and infections: \u03b2-amyloid in inflammasome beyond neurodegeneration. Int J Mol Sci 22(13):6984. https:\/\/doi.org\/10.3390\/ijms22136984","DOI":"10.3390\/ijms22136984"},{"issue":"8","key":"2994_CR88","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1096\/fj.11-197194","volume":"26","author":"SD Skaper","year":"2012","unstructured":"Skaper SD, Giusti P, Facci L (2012) Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 26(8):3103\u20133117. https:\/\/doi.org\/10.1096\/fj.11-197194","journal-title":"FASEB J"},{"key":"2994_CR89","doi-asserted-by":"publisher","unstructured":"Territo PR, Zarrinmayeh H (2021) P2X7 receptors in neurodegeneration: potential therapeutic applications from basic to clinical approaches. Front Cell Neurosci 15:617036. https:\/\/doi.org\/10.3389\/fncel.2021.617036","DOI":"10.3389\/fncel.2021.617036"},{"issue":"November","key":"2994_CR90","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.11.010","volume":"326","author":"BS Thawkar","year":"2018","unstructured":"Thawkar BS, Kaur G (2018) Inhibitors of NF-\u03baB and P2X7\/NLRP3\/caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer\u2019s disease. J Neuroimmunol 326(November):62\u201374. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.11.010","journal-title":"J Neuroimmunol"},{"key":"2994_CR91","doi-asserted-by":"publisher","unstructured":"Tohidpour A et al (2017) Neuroinflammation and infection: molecular mechanisms associated with dysfunction of neurovascular unit. Front Cell Infect Microbiol 7:276. https:\/\/doi.org\/10.3389\/fcimb.2017.00276","DOI":"10.3389\/fcimb.2017.00276"},{"issue":"22","key":"2994_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21228489","volume":"21","author":"M Trang","year":"2020","unstructured":"Trang M, Schmalzing G, M\u00fcller CE, Markwardt F (2020) Dissection of P2X4 and P2X7 receptor current components in BV-2 microglia. Int J Mol Sci 21(22):1\u201320. https:\/\/doi.org\/10.3390\/ijms21228489","journal-title":"Int J Mol Sci"},{"key":"2994_CR93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbi.2021.02.012","volume":"94","author":"R Troubat","year":"2021","unstructured":"Troubat R et al (2021) Brain immune cells characterization in UCMS exposed P2X7 knock-out mouse. Brain Behav Immun 94:159\u2013174. https:\/\/doi.org\/10.1016\/j.bbi.2021.02.012","journal-title":"Brain Behav Immun"},{"key":"2994_CR94","unstructured":"Vaca MJA et al (2018) P2x7 modulators. US10150765B2 11th Dec 2018. https:\/\/patents.google.com\/patent\/US10150765B2\/en"},{"issue":"10","key":"2994_CR95","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00259-019-04369-6","volume":"46","author":"D Van Weehaeghe","year":"2019","unstructured":"Van Weehaeghe D et al (2019) [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson\u2019s disease and healthy volunteers. Eur J Nucl Med Mol Imaging 46(10):2051\u20132064. https:\/\/doi.org\/10.1007\/s00259-019-04369-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2994_CR96","doi-asserted-by":"publisher","unstructured":"Volont\u00e9 C, Amadio S, Liguori F, Fabbrizio P (2020) Duality of P2X7 receptor in amyotrophic lateral sclerosis. Front Pharmacol 11:1148. https:\/\/doi.org\/10.3389\/fphar.2020.01148","DOI":"10.3389\/fphar.2020.01148"},{"issue":"2","key":"2994_CR97","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3892\/mmr.2016.6070","volume":"15","author":"XH Wang","year":"2017","unstructured":"Wang XH, Xie X, Luo XG, Shang H, He ZY (2017) Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson\u2019s disease. Mol Med Rep 15(2):768\u2013776. https:\/\/doi.org\/10.3892\/mmr.2016.6070","journal-title":"Mol Med Rep"},{"key":"2994_CR98","doi-asserted-by":"publisher","unstructured":"Yang D (2017) Targeting the p2x7 receptor in age-related macular degeneration. Vision 1(2):11. https:\/\/doi.org\/10.3390\/vision1020011","DOI":"10.3390\/vision1020011"},{"key":"2994_CR99","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.5213\/inj.1938184.092","volume":"23","author":"SH Yang","year":"2019","unstructured":"Yang SH (2019) Cellular and molecular mediators of neuroinflammation in Alzheimer disease. Int Neurourol J 23:S54\u2013S62. https:\/\/doi.org\/10.5213\/inj.1938184.092","journal-title":"Int Neurourol J"},{"key":"2994_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1536012120927609","volume":"19","author":"H Zarrinmayeh","year":"2020","unstructured":"Zarrinmayeh H, Territo PR (2020) Purinergic receptors of the central nervous system: biology, PET ligands, and their applications. Mol Imaging 19:1\u201326. https:\/\/doi.org\/10.1177\/1536012120927609","journal-title":"Mol Imaging"},{"key":"2994_CR101","unstructured":"Zhao Y, Naik H (2021) Methods of treating neuropathic pain. US20210154170. 27th May 2021. https:\/\/patents.google.com\/patent\/US20210154170\/en"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-02994-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-02994-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-02994-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:37:28Z","timestamp":1718113048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-02994-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-02994-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have their consent to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}